Merck Pauses Enrollment of Its Blood Cancer Study, Citing Deaths 21 minutes ago

Merck Pauses Enrollment of Its Blood Cancer Study, Citing Deaths 21 minutes ago


Merck & Co. said it's pausing enrollment of a study of its key cancer immunotherapy drug, Keytruda, in patients with a form of blood cancer following reports of patient deaths among those taking Merck's drug.



from Biotech News